Biocon Biologics has successfully simplified its capital structure, leading to an upgrade in its ratings by S&P Global. By ...

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

S&P Global Ratings has upgraded Biocon Biologics' long-term issuer credit rating to BB+ from BB, citing a simplified capital structure and improved financial position.

Biocon Biologics Limited, a fully integrated, global biosimilars company and subsidiary of Biocon announced that S&P Global Ratings has upgraded the company’s long-term issuer credit rating to ‘BB+’ ...

S&P Global Ratings upgrades Biocon Biologics with a stable outlook after debt reduction and capital structure simplification.

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Biocon Biologics, subsidiary of Biocon today announced that S&P Global Ratings has upgraded the Company's long-term issuer credit rating to 'BB+' from 'BB ...

Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan ...

Pharma major Biocon is set to announce its Q3FY26 results on 12 Feb 2026. Brokerage reports project a strong Q3FY26 for ...

Bengaluru: Biocon Limited has successfully concluded a Rs 4,150 crore (approximately USD 460 million) equity fundraise ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars ...

Shares of parent company Biocon gained 1.34%, to close at Rs.370.15 on BSE on Wednesday, following the ratings announcement.